Oral drug for active diffuse scleroderma
Part of Skin clinical trials.
This trial tests an experimental oral tablet (TollB-001) for people with active diffuse systemic sclerosis, a type of scleroderma that causes skin thickening and internal organ damage. The goal is to see if the drug can help control the disease and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with systemic sclerosis (scleroderma).
- You have the diffuse type of scleroderma, which affects the skin and internal organs.
- Your disease is active, meaning you are having symptoms or signs of worsening.
- You can take oral tablets and are willing to follow the study plan.
- You have not had a scleroderma kidney crisis in the last 6 months and have no history of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called OL-CD19-GDT for people with systemic sclerosis or Sjögren's syndrome that hasn't responded to standard therapies. It aims to see if the treatment is safe and might help control the disease.
This trial tests a new drug, GB261, for people with systemic sclerosis (a condition that causes thickening and hardening of the skin and can affect internal organs). It aims to see if it can help when other treatments haven't worked well enough.
This study tests whether blocking a protein called TL1A can help reduce skin thickening and improve the immune system in people with systemic sclerosis (a condition where skin becomes hard and thick). Researchers will compare skin and blood samples from people with systemic sclerosis to healthy volunteers.
This trial tests a new investigational medicine called PRO-203 for people with systemic sclerosis (scleroderma). It aims to see if the medicine can help control active disease that hasn't responded to other treatments.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
This trial tests whether special cells from umbilical cord (UC-MSC) can help treat systemic sclerosis—a disease that causes skin and organ hardening. If you have early systemic sclerosis that hasn't improved enough with standard treatments, this study may offer a new option.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.